may 17, 2018 -- the fda has approved the first in a new class of migraine drugs that aim to fight painful.
the total amount paid out in life claims was £129.4m, with £13.46m paid in terminal illness claims..español...
following close on aimovig's heels are three other drugs that target cgrp: fremanezumab, galcanezumab, and eptinezumab (which is given by iv).